GSK Reports EMA’s Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma

 GSK Reports EMA’s Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma

Shots:

  • The MAA is based on DREAMM-2 P-II study (DRiving Excellence in Approaches to Multiple Myeloma) study which involves assessing of Belantamab Mafodotin in heavily pre-treated patients with MM who were refractory to an immunomodulatory drug and a proteasome inhibitor and were refractory and/or intolerant to an anti-CD38Ab
  • The study resulted in 31% ORR with a 2.5 mg/kg regimen of single agent belantamab mafodotin with consistent safety and tolerability profile, published in The Lancet Oncology
  • Belantamab Mafodotin is an anti-B cell maturation antigen (BCMA) mAb conjugated to the cytotoxic agent auristatin F via non-cleavable linker and has been accepted for accelerated assessment by the EMA’s CHMP, also received EMA’s PRIME designation in 2017

Click here to read full press release/ article | Ref: GSK | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post